Bayer awards incubator opportunity to Genvor
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Advertisement
Bayer announced that the company has selected Genvor Inc., a US-based crop protection business, as the recipient of its first Golden Ticket award. Genvor will receive year-long access to lab space and equipment at Bayer’s LifeHub California @AgStart, one of the premier U.S. AgriFoodTech innovation ecosystems. This will allow Genvor to connect with Bayer mentors and experts in Bayer’s global innovator network.
In addition to their work with biological sprays, Genvor is working with antimicrobial peptide (AMP) technology to make small changes within a genome that could amplify disease resistance and enhance nutrition, from seed to sprout. These seed traits are another way that Genvor is working to provide increased disease resistance and nutrition for crops.
“We’re excited that Genvor has been selected as the winner of our Golden Ticket program, and that we will be working with them to scale and grow their innovations,” said Phil Taylor, Director of Open Innovation and Outreach for Bayer’s Crop Science Division. “Genvor’s proprietary use of antimicrobial peptide technology takes advantage of pathways built-in to crops and has the potential to deliver broad spectrum biological sprays for effective controls of many plant diseases.”
The Golden Ticket program is one of the many ways that Bayer is working with start-ups from around the world to accelerate the delivery of agricultural innovation to farmers. In its first year, it focuses on areas of regenerative agriculture, novel crop protection and efficiency approaches, advanced breeding technologies, and applications of synthetic biology. From a broad field of applicants representing 34 cutting edge technologies and approaches, Genvor was selected to receive the award for their ground-breaking approach to crop protection. Through Bayer’s LifeHub California @AgStart, Genvor will also gain access to excellent equipment, resources, and mentorship as they bring their technologies to market.
“Receiving Bayer’s Golden Ticket is a pivotal moment for us, propelling our pioneering peptide design innovations in crop protection,” said Chad Pawlak, CEO of Genvor. “This support will accelerate our journey towards commercialization, enhancing agricultural sustainability and delivering tangible benefits for farmers and the environment globally.”
Bayer’s global network of LifeHubs is located in hotspots of innovation including Monheim, Lyon, Barcelona, California, and Bangalore. In support of the Crop Science mission, they focus on areas of critical innovation in agriculture such as solutions for smallholder farmers, transparency, and sustainability.
Bayer’s LifeHub California @AgStart focuses on innovations within food production systems, including bringing food to market and new technologies. As a part of the larger AgStart facility which hosts the largest wet-lab incubator for startup companies in California’s Central Valley region, the LifeHub also connects the knowledge and experience of Bayer scientists to the leading innovators of the area to assist in developing new technologies.
“We look forward to welcoming Genvor into our community and connecting them into our region’s innovation ecosystem,” said Sudhee Lakshmana, Director at AgStart. “Genvor’s selection for Bayer’s Golden Ticket award is a testament to Genvor’s potential to make a significant impact with their innovation.”
Other news from the department research and development
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma - First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM
First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years
Siegfried opens new global R&D Center for Drug Substances in Evionnaz - New facility to drive development excellence and further growth
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery - First successful simultaneous 10-target multiplex-screening
BioMed X Institute launches new cancer collaboration with Daiichi Sankyo - Call for proposals from researchers around the world to take part in this ambitious project
CureVac enters clinical phase with mRNA vaccine - First data expected on intramuscular application of the newly developed vaccine
New drug candidates reverse drug resistance in multiple myeloma in preclinical models
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
NIH clinical trial of remdesivir to treat COVID-19 begins
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease
